NCQA publishes proposed changes to HEDIS measures for MY 2022

The National Committee for Quality Assurance (NCQA) is accepting comments through March 11 on proposed changes for HEDIS® Measurement Year 2022 (MY 2022), which will be published in August 2021. Jamison Gillitzer, product director for Cotiviti’s quality improvement solutions, summarizes the important details on proposed new measures, changes to existing measures, and measures proposed for retirement for plans that report HEDIS data.

Implement a year-round measurement and reporting program that significantly improves health plan rankings. Learn more about Cotiviti's Quality Intelligence from our fact sheet.

Read the fact sheet

Future of HEDIS

Introduction of Race and Ethnicity Stratification​ into select HEDIS Measures

NCQA is proposing to introduce race and ethnicity stratifications to five HEDIS measures for MY 2022 with an expansion to a minimum of 15 measures by MY 2024 to help identify and reduce disparities in care. As the agency states, “this effort builds on NCQA’s existing work dedicated to advancing health equity in data and quality measurement.” Candidate measures for MY 2022 include:

  • Controlling High Blood Pressure (CBP)
  • Comprehensive Diabetes Care (CDC)
    • HbA1c <8% indicator
    • Eye Exam
  • Antidepressant Medication Management (AMM)
  • Follow-Up After Emergency Department Visit for People With Multiple High-Risk Chronic Conditions (FMC)
  • Adults’ Access to Preventive/Ambulatory Health Services (AAP)
  • Prenatal and Postpartum Care (PPC)
  • Well-Child Visits in the First 30 Months of Life (W30)
  • Child and Adolescent Well-Care Visits (WCV)
  • Mental Health Utilization (MPT)

Roadmap for Electronic Clinical Data Systems (ECDS) Reporting Method

NCQA plans to add the ECDS reporting standard to three additional existing measures for MY 2022. As part of a larger strategy to encourage and improve health information exchange, NCQA also proposes removing traditional reporting from measures currently specified for ECDS.

Measure Name

Summary of Proposed Changes

Childhood Immunization Status (CIS)

Immunizations for Adolescents (IMA)

Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)

Allow ECDS reporting for MY 2022​

Breast Cancer Screening

Follow-Up Care for Children Prescribed ADHD Medication (ADD)

Choose ECDS or Admin reporting for MY 2022, ECDS only MY 2023

Colorectal Cancer Screening (COL)

Choose ECDS or Hybrid reporting for MY 2023, ECDS only MY 2024 (Hybrid removed)​

Cervical Cancer Screening (CCS)

Add optional ECDS reporting for MY 2023​


Noting that it will “enable more efficient data exchange, reduce provider burden, and align with other quality measurement use cases,” NCQA is also continuing the gradual transition to the Fast Healthcare Interoperability Resources (FHIR) data model.

Changes to existing HEDIS measures

NCQA is proposing several changes to measures related to acute hospitalization utilization, use of imaging studies for low back pain, mental health utilization, alcohol and drug use, and diabetes care for MY 2022.

Measure Name

Summary of Proposed Changes

Acute Hospital Utilization (AHU)

  • Exclude planned hospitalizations
  • Remove reporting of separate medical and surgical categories, retaining just the total hospitalization rate

Use of Imaging Studies for Low Back Pain (LBP)

  • Expand the upper age limit from 50 to 74 years
  • Apply four additional clinical exclusions: any history of osteoporosis; any history of spinal surgery; any history of ankylosing spondylitis; and fragility fracture within 90 days prior to index date
  • Apply two cross-cutting exclusions: palliative care and advanced Illness/frailty

Mental Health Utilization (MPT)

  • Rename to Diagnosed Mental Health Disorders
  • Change from utilization to diagnosis prevalence, follow the reporting guidelines for Effectiveness of Care Measures​
  • Consider mental health diagnosis from any position (instead of principal only)​
  • Remove mental health practitioner requirements

Identification of Alcohol and Other Drug Services (IAD)

  • Rename to Diagnosed Substance-Related Disorders
  • Change from utilization to diagnosis prevalence, follow the reporting guidelines for Effectiveness of Care Measures

Initiation and Engagement of Alcohol and

Other Drug Abuse or Dependence Treatment (IET)

  • Change to episode-based instead of member-based​
  • Rename to Initiation and Engagement of Substance Use Disorder Treatment
  • Add stratification for “behavioral health complexity” ​
  • Modify age stratifications
  • When categorizing the drug cohort, choose the principal diagnosis or the position closest to the principal position​

Follow-up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (FUA)

  • Rename to Follow-up After Emergency Department Visit for Substance Use
  • Update denominator and numerator criteria to look in any diagnosis position​
  • Add additional follow-up options to numerator that don’t require an SUD diagnosis

Comprehensive Diabetes Care (CDC)

  • Retire the HbA1c Testing numerator​
  • Move the optional exclusions to required exclusions​
  • Split the remaining numerators into three separate hybrid measures​:
    • Hemoglobin A1c Control for Patients with Diabetes​ (HBD)
      • Two numerators: HbA1c control (<8.0%) and HbA1c poor control (>9.0%)​
    • Eye Exam for Patients with Diabetes​ (EED)
      • Remove Diabetic Retinal Screening in the year prior with a negative result from the admin numerator​
    • Blood Pressure Control for Patients with Diabetes​ (BPD)
      • Replace numerator requirement for BP reading setting (outpatient, telephone, online, remote) with exclusion of BP readings in acute inpatient or ED visit settings

New HEDIS measures being introduced

NCQA is proposing the addition of three new measures for MY 2022.

Measure Name


Advance Care Planning (ACP)

  • The percentage of adults 66–80 years old with advanced illness, frailty or palliative care, and adults 81 years of age and older, who had advance care planning during the measurement year
  • Medicare product line only

Deprescribing of Benzodiazepines in Older Adults (DBO)

  • The percentage of Medicare members 67 years of age and older who were dispensed benzodiazepines and experienced a decrease in benzodiazepine dose during the measurement year.
  • Three numerators: ≥10% Reduction, ≥25% Reduction, ≥50% Reduction​
  • Medicare product line only

Antibiotic Utilization for Acute Respiratory Conditions (AXR)

  • The percentage of episodes for members 3 months of age and older with a diagnosis of an acute respiratory condition that resulted in an antibiotic dispensing event.
  • Proposed replacement for Antibiotic Utilization (ABX)
  • Commercial, Medicaid, and Medicare product lines

Ready to comment?

NCQA seeks public feedback on these proposed new HEDIS measures, revisions to existing measures, proposed measure retirement, and initiatives by 11:59 p.m. (ET), Thursday, March 11. Submit all comments via NCQA’s Public Comment website.

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).


Jamison Gillitzer
Jamison is a senior product director supporting Cotiviti’s Quality and Performance solution suite. His primary responsibilities are the successful delivery of our quality solutions to ensure they meet clients' needs in support of HEDIS, P4P, and other quality reporting initiatives. He also works to develop and enhance our capabilities to support evolving quality requirements. Jamison has a bachelor's degree in entrepreneurial management from the University of Minnesota and is PMC-III certified.

Read More


Closing the Gap: Improving chronic disease screening and care

Jamison Gillitzer

Nov 28, 2023


Closing the Gap: National Immunization Awareness Month

Jamison Gillitzer

Jul 31, 2023


Closing the Gap: Improving cervical cancer prevention

Jamison Gillitzer

Jan 25, 2023


Webinar: Reviewing HEDIS MY 2021 and looking ahead to MY 2022

Jamison Gillitzer

Jun 30, 2022

Connect with our experts